The Prolyl Hydroxylase Inhibitor BIQ/FG-2216 Stabilises HIF-1 alpha and Upregulates VEGF in vitro: A Potential Strategy For Difficult CTO Lesions in Patients.

Схожі ресурси

• 74 Pro-Angiogenic Effects of the Prolyl-hydroxylase Inhibitor FG-2216/BIQ: Therapeutic Angiogenesis for the Treatment of Chronic Total Occlusions.
  за авторством: Barnett, G, та інші
  Опубліковано: (2014)
• Pro-angiogenic effects of proly-hydroxylase inhibitor FG-2216 and potential for use in a novel strategy of therapeutic angiogenesis for difficult cases of coronary total occlusion
  за авторством: Barnett, G, та інші
  Опубліковано: (2014)
• Enhanced Endothelial Tubule Formation in Response to Proly-Hydroxylase Inhibitor FG-2216: A Step Towards Therapeutic Angiogenesis in Chronic Total Occlusions
  за авторством: Barnett, G, та інші
  Опубліковано: (2012)
• Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents.
  за авторством: Flashman, E, та інші
  Опубліковано: (2010)
• Regulation of HIF: prolyl hydroxylases.
  за авторством: Stolze, I, та інші
  Опубліковано: (2006)